Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
BRIEF-Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide May 31 (Reuters) - Hanmi Pharm Co Ltd 128940.KS:
HANMI PHARM CO - ENTERS LICENSE AGREEMENT WITH LILLY FOR SONEFPEGLUTIDE
HANMI PHARM CO - LILLY OBTAINS EXCLUSIVE GLOBAL RIGHTS TO SONEFPEGLUTIDE EXCLUDING KOREA
HANMI PHARM CO - TO RECEIVE $75 MLN UPFRONT AND UP TO $1.19 BLN IN MILESTONES
Source text: ID:nPre78LC8a
Further company coverage: 128940.KS
((Reuters.briefs@thomsonreuters.com;))
Recent news on Hanmi Pharm
See all newsBrief: Hanmi Pharm To Cancel 28 Billion Won Worth Of Own Shares
Brief: Hanmi Pharm Q3 Operating Profit 37.8 Billion Won, Down 31.3% From Year Earlier
Brief: Hanmi Pharm Co Signs License Out Agreement With Genetech Inc. In U.S.
Brief: Hanmi Pharm Co Enters License Agreement With Eli Lilly For Sonefpeglutide
Brief: Hanmi Pharm Co Ltd Wins 53 Billion Won Order